Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Medical Device Experts

Articles with lock require a subscription to GLG News | Request a free trial
Ken PowellApril 8, 2008
Colorectal Cancer Agreement Between Quest and Epigenomics
Analysis of: Quest Licenses Epigenomics’ Methylation Marker to Develop Blood-Based CRC Test | www.genomeweb.com
Author: Ken Powell, President, Genesis Business Development
Quest Diagnostics (NYSE: DGX) and Epigenomics (Frankfurt Prime Standard: ECX) have entered into a non-exclusive agreement for Quest to use Epigenomics' Septin 9 DNA metylation biomarker for colorectal cancer.  Because this molecular test requires just a simple blood sample, it could result...
April 8, 2008
Insurers and Pharmacy Benefit Management Companies Will Continue Covering Vytorin
Analysis of: Will Insurers Reduce Coverage For Vytorin? | www.pharmalot.com
Author: GLG Expert Contributor
I believe insurers and pharmacy benefit management companies will coverage of Vytorin.  Most likely, it will lose any preferred status, (formulary Tier 2), and move to non-preferred brand, (formulary Tier 3 or Tier 4), depending on the drug reimbursement system in the health plan.  As an example,...
April 8, 2008
Current trends with Venture Capital Funds and IPO's
Analysis of: Venture Activity Hit by U.S. Slowdown | online.wsj.com
Author: GLG Expert Contributor
As a partner @ a VC fund I  see this trend impacting how potential portfolio companies are evaluated.  Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded.  Investment decisons are also being influenced by the potential...
Eric GruffApril 8, 2008
Insurers Should be the First Line of Defense Against Vytorin
Analysis of: Will Insurers Reduce Coverage For Vytorin? | www.pharmalot.com
Author: Eric Gruff, Principal, E4 Consulting
The pharmaceutical industry continues to lay its collective head on the chopping block by pushing drugs like Vytorin that demonstrate at best marginal activity. Insurers have a fiduciary duty to push back against the poor judgement of drugmakers who take advantage of confusion and DTC advertising to...
Eric GruffApril 8, 2008
Pfizer's Melanoma Treatment Setback Has Bigger Implications
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment | online.wsj.com
Author: Eric Gruff, Principal, E4 Consulting
While disappointing for patients and caregivers, Pfizer's loss of a late-stage treatment for melanoma casts an even darker shadow on the ability of pharmaceutical and biotech companies to successfully bring new treatments to market. Coupled with other recent Phase 3 failures, this latest outcome points...
Ken PowellApril 4, 2008
Ovarian Cancer
Analysis of: Ultrasound fails to spot early ovarian cancer | www.yourcancertoday.com
Author: Ken Powell, President, Genesis Business Development
Annual ultrasound, coupled with a CA 125 blood test does not reliably detect ovarian cancer early, at a more curable stage.  A recent study published in the International Journal of Obstetrics and Gynecology highlights the opportunity for an objective, molecular diagnostics ovarian...
Ken PowellApril 2, 2008
MRSA Test Launched in the US
Analysis of: MRSASelect™ Chromogenic Medium | www.medcompare.com
Author: Ken Powell, President, Genesis Business Development
Methicillin resistant staph aureous (MRSA) is responsible for approximately 19,000 deaths per year in the US.  Bio-Rad (AMEX: BIO) recently announced the introduction of its MRSASelect(tm) to identify methicillin resistant staph aureous (MRSA).  MRSA is an infectious bacteria resistant...
Ken PowellApril 1, 2008
Personalized Medicine
Analysis of: Cancer researchers at Manhattan-based St. Vincent’s Comprehensive Cancer Center discover genes that can determine how patients respond to pre-leukemia drug. | www.myelomatreatment.org
Author: Ken Powell, President, Genesis Business Development
Recent news announcing that a team of cancer researchers at Manhattan-based St. Vincent’s Comprehensive Cancer Center, in partnership with the Broad Institute of MIT and the Dana Farber Cancer Institute in Boston, have identified 30 red cell-related genes which determine the effectiveness of using the...
Ken PowellApril 1, 2008
FDA Approves Molecular Respiratory Virus Panels
Analysis of: Molecular Testing for Respiratory Viruses | www.aacc.org
Author: Ken Powell, President, Genesis Business Development
Influenza and respiratory syncytial viruses (RSV) result in a significant number of hospitalizations and deaths.  According to the CDC, influenza alone causes over 200,000 hospitalizations and 36,000 deaths annually.  Quick diagnosis and proper treatment can lead to shorter hospital stays...
Ken PowellMarch 31, 2008
Molecular Diagnostics May Revive Failed Drugs
Analysis of: Genetics May Bring New Life to Failed Drugs | online.wsj.com
Author: Ken Powell, President, Genesis Business Development
Recent advances in molecular diagnostics and genomics may give new life to previously shelved drugs that were unable to successfully complete the development process.  So-called "personalized medicine" stratgies use molecular diagnostic lab tests to identify patient populations that have...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 122

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613